Why the study?
The value of guided anti-P2Y12 therapy in PCI is unclear, as prior meta-analyses lumped together RCTs with heterogeneous designs or included trials not exploring guided therapy.
Does guided anti-P2Y12 therapy reduce major adverse cardiovascular events or major bleeding compared to unguided therapy in patients undergoing PCI?
Does guided anti-P2Y12 therapy reduce major adverse cardiovascular events or major bleeding compared to unguided therapy in patients undergoing PCI?
Genotype-guided anti-P2Y12 therapy reduces MACE without increasing major bleeding in PCI patients, with benefits particularly pronounced in Chinese populations, whereas platelet function test-guided therapy does not show overall MACE reduction.
No takes yet. Share an insight, caveat, or question.
Supports genotype-guided anti-P2Y12 selection post-PCI; confirms MACE reduction without bleeding increase and challenges routine PFT guidance.
Birocchi et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: